Abstract: Provided are compounds of Formula (I?), including compounds of Formulas (I), (II), (III), (IIIA) and (IIIB), wherein L, R1, R3 and n are as defined herein, and pharmaceutically acceptable salts thereof, and methods for their use and production. These compounds can be useful, e.g., in the treatment of disorders responsive to the inhibition of apoptosis signal-regulating kinase 1 (ASK1).

Abstract: An aluminum alloy foil having a composition including, Fe of 1.0% by mass or more and 1.8% by mass or less, Si of 0.01% by mass or more and 0.08% by mass or less, Cu of 0.005% by mass or more and 0.05% by mass or less, Mn of 0.01% by mass or less, and Al. In a crystal orientation analysis per unit area by electron backscatter diffraction (EBSD), a ratio (HAGBs/LAGBs) of a length of high angle grain boundaries (HAGBs) having an orientation difference of 15° or more to a length of low angle grain boundaries (LAGBs) having an orientation difference of 2° or more and less than 15° is more than 2.0, and a Cu orientation density is 40 or less and an R orientation density is 30 or less as a texture.

Abstract: Disclosed are systems and methods for classifying brain lesions based on single point in time imaging, methods for training a machine learning model for classifying brain lesions, and a method of predicting formation of brain lesions based on single point in time imaging. A method of classifying brain lesions based on single point in time imaging can include; accessing patient image data from a single point in time; providing the patient image data as an input to a brain lesion classification model; generating a classification for each of one or more lesions identified in the patient image data; and providing the classification for each of the one or more lesions for display on one or more display devices; wherein the brain lesion classification model is trained using subject image data for a plurality of subjects, the subject image data being captured at two or more points in time.

Abstract: The present invention relates to a method of treating an autoimmune or inflammatory disease or a neurodegenerative disease with an antibody to CD154.

Abstract: Embodiments of an audio distribution module and system provide a compact and rugged audio switching device including a radio control unit in communication with an operator control panel. In various embodiments, an audio switching fabric is included with audio relays for directing the transmission and receipt of audio content between a headset in communication with the operator control panel and one or more radios in communication with the radio control unit, facilitating transmission and receipt of audio communications between the radio(s) and the headset.

Abstract: This disclosure relates to a device to mechanically and electrically connect with a touch screen computing device, such as a tablet computer. The device can include a platform that can be moved into and out of physical contact with a surface of a touch screen. During engagement with the surface, the moveable platform electrically interacts with the touch screen (e.g., via capacitive coupling) to enable detection by the touch screen of contact members (e.g., pegs) even in the absence of user contact with the pegs.

Abstract: Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production.

Abstract: A drug used for treating or preventing cerebral hemorrhage, the drug including, as an active ingredient, a compound represented by the following Formula (I) or a pharmaceutically acceptable salt, ester, or solvate thereof:

Abstract: A system and method are provided for harvesting target biological substances. The system includes a substrate and a first and second channel formed in the substrate. The channels longitudinally extending substantially parallel to each other. A series of gaps extend from the first channel to the second channel to create a fluid communication path passing between a series of columns with the columns being longitudinally separated by a predetermined separation distance. The system also includes a first source configured to selectively introduce into the first channel a first biological composition at a first channel flow rate and a second source configured to selectively introduce into the second channel a second biological composition at a second channel flow rate. The sources are configured to create a differential between the first and second channel flow rates to generate physiological shear rates along the second channel that are bounded within a predetermined range.

Abstract: Methods of the disclosure may include obtaining a first set of medical images at a first time point and a second set of medical images at a second time point, each set including at least two medical images. First and second algorithms may be used to calculate, respectively, first and third brain volume (BV) values at the first time point based on two or more images from the first set of medical images and second and fourth BV values at the second time point based on two or more images from the second set of medical images. A mathematical weight may be applied to at least one of the first, second, third, or fourth BV values. The first and third BV values may be averaged, and the second and fourth BV values may be averaged to determine overall BV values at the first and second time points, respectively.

Abstract: Various aspects and embodiments of the present disclosure relate to the purification antibodies by hydrophobic interaction chromatography under no-salt conditions.

Abstract: An aluminum alloy foil having a composition, including Fe: 1.2% by mass or more and 1.8% by mass or less, Si: 0.05% by mass or more and 0.15% by mass or less, Cu: 0.005% by mass or more and 0.10% by mass or less, and Mn: 0.01% by mass or less, with a remainder being Al and inevitable impurities. An average crystal grain size of the aluminum alloy foil is 20 to 30 ?m, a maximum crystal grain size/the average crystal grain size is ?3.0, a Cube orientation density is 5 or more, a Cu orientation density is 20 or less, and an R orientation density is 15 or less.

Abstract: Aspects of the invention are directed to arginine-free polypeptide-containing compositions and methods for treating disorders associated with inflammation or the autoimmune response. In particular, the polypeptide is etanercept.

Abstract: The present disclosure provides anti-transferrin receptor antibodies, compositions comprising the same and methods of their use. This disclosure also provides polynucleotides and vectors encoding the anti-transferrin receptor antibodies and cells comprising the same, methods of making the antibodies, and molecules comprising the antibodies.

Abstract: Provided are crystalline forms of (R)-1-(tert-butyl)-N-(8-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-2-(oxetan-3-yl)-2,3,4,5-tetrahydro-1H-benzo[c]azepin-5-yl)-1H-1,2,3-triazole-4-carboxamide, pharmaceutical compositions, methods of use and methods of making thereof.

Abstract: Provided are compounds of Formula (I): including compounds of Formulas (II), (III) and (IV), wherein X, R1, R2, R3 and n are as defined herein, and pharmaceutically acceptable salts thereof, and methods for their use and production. These compounds can be useful, e.g., in the treatment of disorders responsive to the inhibition of apoptosis signal-regulating kinase 1 (ASK1).

Abstract: An aluminum brazing sheet for flux-free brazing having a multilayer structure of two or more layers including at least one core material layer and one brazing material layer, wherein the brazing material layer is positioned on one or both sides of the core material layer and on an outermost surface of the brazing sheet. The brazing material layer is made of an Al—Si—Mg—X brazing material containing: in mass%, 0.05 to 2.0% of Mg, and 2.0 to 14.0% of Si, and further containing one or more of 0.01 to 0.3% of Bi, Ga, Sn, In and Pb, a total amount of Bi, Ga, Sn, In and Pb being 0.5% or less. X indicates one or more of Bi, Ga, Sn, In and Pb.

Abstract: Disclosed herein are antisense compounds and methods for decreasing Tau mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate Tau-associated diseases, disorders, and conditions.

Abstract: Disclosed herein are methods for reducing expression of Tau mRNA and protein in an animal with Tau antisense compounds. Also disclosed are methods for modulating splicing of Tau mRNA in an animal with Tau antisense compounds. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Examples of neurodegenerative diseases that can be treated, prevented, and ameliorated with the administration Tau antisense oligonucleotides include Alzheimer's Disease, Fronto-temporal Dementia (FTD), FTDP-17, Progressive Supranuclear Palsy, Chronic Traumatic Encephalopathy, Epilepsy, and Dravet's Syndrome.

Abstract: A new integrated method to capture polluted CO2 using CaO produced from phosphogypsum calcination using sulfur as non-CO2 fuel where (1) both pollutants of phosphogypsum and CO2 are transformed into environmentally neutral or useful products such as limestone or clinker and sulfuric acid; (2) low-CO2 CaO produced from calcination of phosphogypsum with sulfur as fuel can be used to produce low-CO2 clinker that replaces the use of high-CO2 limestone as raw material; (3) the use of sulfur as fuel to calcine phosphogypsum allows the production of low-cost sulfuric acid.